FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045368439> ?p ?o ?g. }

• W2045368439 abstract "Background Many deaths from cancer are caused by metastatic burden. Prognosis and survival rates vary, but survival beyond 5 years of patients with untreated metastatic disease in the liver is rare. Treatment for liver metastases has largely been surgical resection, but this is feasible in only approximately 20–30% of people. Non-surgical alternatives to treat some liver metastases can include various forms of ablative therapies and other targeted treatments. Objectives To evaluate the clinical effectiveness and cost-effectiveness of the different ablative and minimally invasive therapies for treating liver metastases. Data sources Electronic databases including MEDLINE, EMBASE and The Cochrane Library were searched from 1990 to September 2011. Experts were consulted and bibliographies checked. Review methods Systematic reviews of the literature were undertaken to appraise the clinical effectiveness and cost-effectiveness of ablative therapies and minimally invasive therapies used for people with liver metastases. Studies were any prospective study with sample size greater than 100 participants. A probabilistic model was developed for the economic evaluation of the technologies where data permitted. Results The evidence assessing the clinical effectiveness and cost-effectiveness of ablative and other minimally invasive therapies was limited. Nine studies of ablative therapies were included in the review; each had methodological shortcomings and few had a comparator group. One randomised controlled trial (RCT) of microwave ablation versus surgical resection was identified and showed no improvement in outcomes compared with resection. In two prospective case series studies that investigated the use of laser ablation, mean survival ranged from 41 to 58 months. One cohort study compared radiofrequency ablation with surgical resection and five case series studies also investigated the use of radiofrequency ablation. Across these studies the median survival ranged from 44 to 52 months. Seven studies of minimally invasive therapies were included in the review. Two RCTs compared chemoembolisation with chemotherapy only. Overall survival was not compared between groups and methodological shortcomings mean that conclusions are difficult to make. Two case series studies of laser ablation following chemoembolisation were also included; however, these provide little evidence of the use of these technologies in combination. Three RCTs of radioembolisation were included. Significant improvements in tumour response and time to disease progression were demonstrated; however, benefits in terms of survival were equivocal. An exploratory survival model was developed using data from the review of clinical effectiveness. The model includes separate analyses of microwave ablation compared with surgery and radiofrequency ablation compared with surgery and one of radioembolisation in conjunction with hepatic artery chemotherapy compared with hepatic artery chemotherapy alone. Microwave ablation was associated with an incremental cost-effectiveness ratio (ICER) of £3664 per quality-adjusted life-year (QALY) gained, with microwave ablation being associated with reduced cost but also with poorer outcome than surgery. Radiofrequency ablation compared with surgical resection for solitary metastases < 3 cm was associated with an ICER of –£266,767 per QALY gained, indicating that radiofrequency ablation dominates surgical resection. Radiofrequency ablation compared with surgical resection for solitary metastases ≥ 3 cm resulted in poorer outcomes at lower costs and a resultant ICER of £2538 per QALY gained. Radioembolisation plus hepatic artery chemotherapy compared with hepatic artery chemotherapy was associated with an ICER of £37,303 per QALY gained. Conclusions There is currently limited high-quality research evidence upon which to base any firm decisions regarding ablative therapies for liver metastases. Further trials should compare ablative therapies with surgery, in particular. A RCT would provide the most appropriate design for undertaking any further evaluation and should include a full economic evaluation, but the group to be randomised needs careful selection. Source of funding Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research." @default.
• W2045368439 created "2016-06-24" @default.
• W2045368439 creator A5000738567 @default.
• W2045368439 creator A5007992268 @default.
• W2045368439 creator A5029572086 @default.
• W2045368439 creator A5034409883 @default.
• W2045368439 creator A5049285439 @default.
• W2045368439 creator A5053498286 @default.
• W2045368439 creator A5056345420 @default.
• W2045368439 creator A5065391400 @default.
• W2045368439 creator A5065594332 @default.
• W2045368439 creator A5069847534 @default.
• W2045368439 creator A5072527393 @default.
• W2045368439 creator A5074300091 @default.
• W2045368439 creator A5075935196 @default.
• W2045368439 date "2014-01-01" @default.
• W2045368439 modified "2023-10-15" @default.
• W2045368439 title "The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation" @default.
• W2045368439 doi "https://doi.org/10.3310/hta18070" @default.
• W2045368439 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781443" @default.
• W2045368439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24484609" @default.
• W2045368439 hasPublicationYear "2014" @default.
• W2045368439 type Work @default.
• W2045368439 sameAs 2045368439 @default.
• W2045368439 citedByCount "46" @default.
• W2045368439 countsByYear W20453684392014 @default.
• W2045368439 countsByYear W20453684392015 @default.
• W2045368439 countsByYear W20453684392016 @default.
• W2045368439 countsByYear W20453684392017 @default.
• W2045368439 countsByYear W20453684392018 @default.
• W2045368439 countsByYear W20453684392019 @default.
• W2045368439 countsByYear W20453684392020 @default.
• W2045368439 countsByYear W20453684392021 @default.
• W2045368439 countsByYear W20453684392022 @default.
• W2045368439 countsByYear W20453684392023 @default.
• W2045368439 crossrefType "journal-article" @default.
• W2045368439 hasAuthorship W2045368439A5000738567 @default.
• W2045368439 hasAuthorship W2045368439A5007992268 @default.
• W2045368439 hasAuthorship W2045368439A5029572086 @default.
• W2045368439 hasAuthorship W2045368439A5034409883 @default.
• W2045368439 hasAuthorship W2045368439A5049285439 @default.
• W2045368439 hasAuthorship W2045368439A5053498286 @default.
• W2045368439 hasAuthorship W2045368439A5056345420 @default.
• W2045368439 hasAuthorship W2045368439A5065391400 @default.
• W2045368439 hasAuthorship W2045368439A5065594332 @default.
• W2045368439 hasAuthorship W2045368439A5069847534 @default.
• W2045368439 hasAuthorship W2045368439A5072527393 @default.
• W2045368439 hasAuthorship W2045368439A5074300091 @default.
• W2045368439 hasAuthorship W2045368439A5075935196 @default.
• W2045368439 hasBestOaLocation W20453684391 @default.
• W2045368439 hasConcept C112930515 @default.
• W2045368439 hasConcept C126322002 @default.
• W2045368439 hasConcept C141071460 @default.
• W2045368439 hasConcept C168563851 @default.
• W2045368439 hasConcept C17744445 @default.
• W2045368439 hasConcept C189708586 @default.
• W2045368439 hasConcept C19617505 @default.
• W2045368439 hasConcept C199539241 @default.
• W2045368439 hasConcept C2776478404 @default.
• W2045368439 hasConcept C2779473830 @default.
• W2045368439 hasConcept C3019080777 @default.
• W2045368439 hasConcept C509974204 @default.
• W2045368439 hasConcept C535046627 @default.
• W2045368439 hasConcept C71924100 @default.
• W2045368439 hasConcept C95190672 @default.
• W2045368439 hasConceptScore W2045368439C112930515 @default.
• W2045368439 hasConceptScore W2045368439C126322002 @default.
• W2045368439 hasConceptScore W2045368439C141071460 @default.
• W2045368439 hasConceptScore W2045368439C168563851 @default.
• W2045368439 hasConceptScore W2045368439C17744445 @default.
• W2045368439 hasConceptScore W2045368439C189708586 @default.
• W2045368439 hasConceptScore W2045368439C19617505 @default.
• W2045368439 hasConceptScore W2045368439C199539241 @default.
• W2045368439 hasConceptScore W2045368439C2776478404 @default.
• W2045368439 hasConceptScore W2045368439C2779473830 @default.
• W2045368439 hasConceptScore W2045368439C3019080777 @default.
• W2045368439 hasConceptScore W2045368439C509974204 @default.
• W2045368439 hasConceptScore W2045368439C535046627 @default.
• W2045368439 hasConceptScore W2045368439C71924100 @default.
• W2045368439 hasConceptScore W2045368439C95190672 @default.
• W2045368439 hasFunder F4320319994 @default.
• W2045368439 hasIssue "7" @default.
• W2045368439 hasLocation W20453684391 @default.
• W2045368439 hasLocation W20453684392 @default.
• W2045368439 hasLocation W20453684393 @default.
• W2045368439 hasLocation W20453684394 @default.
• W2045368439 hasOpenAccess W2045368439 @default.
• W2045368439 hasPrimaryLocation W20453684391 @default.
• W2045368439 hasRelatedWork W125306840 @default.
• W2045368439 hasRelatedWork W1965897301 @default.
• W2045368439 hasRelatedWork W1987742652 @default.
• W2045368439 hasRelatedWork W2189666756 @default.
• W2045368439 hasRelatedWork W2747457586 @default.
• W2045368439 hasRelatedWork W2992845476 @default.
• W2045368439 hasRelatedWork W3184554080 @default.
• W2045368439 hasRelatedWork W3208928737 @default.
• W2045368439 hasRelatedWork W4292341104 @default.
• W2045368439 hasRelatedWork W4294636802 @default.
• W2045368439 hasVolume "18" @default.
• W2045368439 isParatext "false" @default.

• next